Quick Answer
Grace Therapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
Grace Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.79 | +41.5% |
| 2024 | -$1.35 | +76.4% |
| 2023 | -$5.71 | -2014.8% |
| 2022 | -$0.27 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.14 | +61.1% | -133.3% |
| September 30, 2025 | -$0.06 | +80.0% | +71.4% |
| June 30, 2025 | -$0.21 | +12.5% | +41.7% |
| December 31, 2024 | -$0.36 | -71.4% | -20.0% |
| September 30, 2024 | -$0.30 | +30.2% | -25.0% |
| June 30, 2024 | -$0.24 | +55.6% | -14.3% |
| December 31, 2023 | -$0.21 | +59.6% | +51.2% |
| September 30, 2023 | -$0.43 | +34.8% | +20.4% |
- Grace Therapeutics, Inc. showed an increase of +41.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Grace Therapeutics, Inc.’s diluted eps has declined by 192.6% (from $0.27 per share (loss) to $0.79 per share (loss)).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: